PURPOSE: The incidence of anaplastic lymphoma kinase (ALK) rearrangement in pulmonary sarcomatoid carcinoma (PSC) is controversial. In this study, we aimed to reveal the reliable frequency and the clinical-pathologic characteristics of pulmonary sarcomatoid carcinoma (PSC) with ALK rearrangement in Chinese population, and to provide insight into the translatability of anti-ALK treatment in this treatment-refractory disease. METHODS: Immunohistochemistry (IHC) using a Ventana anti-ALK (D5F3) rabbit monoclonal antibody was performed in 141 PSC specimens collected from multiple medical centers. IHC-positive cases were then confirmed using ALK fluorescent in situ hybridization (FISH). The incidence rates and clinical-pathologic characteristics of ALK-rearranged PSC were then analyzed. Response to ALK inhibitor crizotinib in a patient with ALK-rearranged PSC was evaluated according to the response evaluation criteria for solid tumors (RECIST) version 1.1. RESULTS: Five of 141 (3.5%) of PSCs showed ALK rearrangement-positive by IHC and then were confirmed by FISH. Two were carcinosarcomas and the other three were pulmonary pleomorphic carcinoma (PPC). Strong positive ALK rearrangement was observed in both the epithelioid and sarcomatoid components. The median age of ALK-positive patients was younger than that of ALK-negative patients. PSCs in never-smokers were more likely to harbor ALK rearrangement than those in former or current smokers (P < .05). A 40-year-old woman diagnosed with ALK-rearranged PPC experienced a partial response (-32%) to the ALK inhibitor crizotinib. CONCLUSIONS: The incidence rates of ALK rearrangement in PSC in the Chinese population are similar to those of other subtypes of NSCLC. PSCs in younger never-smokers are more often to harbor ALK rearrangement. ALK inhibitors may serve as an effective treatment for ALK-rearranged PSC.
基金：
Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2014A030310053]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China;[2]State Key Lab Oncol South, Guangzhou, Guangdong, Peoples R China;[3]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China;[2]State Key Lab Oncol South, Guangzhou, Guangdong, Peoples R China;[3]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Guangdong, Peoples R China;[11]Cent S Univ, Dept Radiat Oncol, Hunan Canc Hosp, Changsha, Hunan, Peoples R China;[12]Cent S Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China;[13]Key Lab Translat Radiat Oncol, Changsha, Hunan, Peoples R China;[14]Hunan Canc Hosp, Dept Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
推荐引用方式(GB/T 7714)：
Chen Xinru,Zhang Yu,Lu Jiabin,et al.Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor[J].TRANSLATIONAL ONCOLOGY.2017,10(2):115-120.doi:10.1016/j.tranon.2016.11.009.
APA：
Chen, Xinru,Zhang, Yu,Lu, Jiabin,Xu, Chunwei,Liang, Jianzhong...&Chen, Likun.(2017).Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor.TRANSLATIONAL ONCOLOGY,10,(2)
MLA：
Chen, Xinru,et al."Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor".TRANSLATIONAL ONCOLOGY 10..2(2017):115-120
